Abstract:Novel amide derivatives as soluble epoxide hydrolase inhibitors were developed. The in‐vitro assay revealed that most of the compounds exhibited moderate to high sEH inhibitory activity. The docking studies were in accordance with biological assays that showed all compounds fit well into the hydrolase active site of sEH and interact with key amino acid residues in the enzyme catalytic site. Soluble epoxide hydrolase (sEH) enzyme has been proposed as a promising target for the treatment of several peripheral inflammatory‐related diseases. The most potent sEH inhibitors are urea or amide‐based which play active‐site transition state mimic and often suffer from poor solubility and low bioavailability. Therefore, the development of novel sEH inhibitors with improved pharmacokinetic specification is a great deal of attention. In this study, amide‐based sEH inhibitors bearing N′‐acetylacetohydrazide/oxadiazole moieties as the primary (P1) and carboxyl/amide as secondary pharmacophores (P2) were designed, synthesized, and biologically evaluated. All the structures were confirmed via recruiting spectral data. Docking results demonstrated that the primary pharmacophore (P1) fit properly in the corresponding binding site of the enzyme, possessing appropriate distances for effective hydrogen bonding to the crucial amino acids, including Asp335. In agreement with the findings of docking studies, a number of compounds were found to possess moderate to high in‐vitro sEH inhibitory activities, and two compounds were identified as the most potent inhibitors with IC50 values of 7.8 and 10.98 nM, respectively. Furthermore, ADME properties of the newly designed analogs were analyzed in silico and the results showed that these compounds have the proper potential for being developed as new sEH inhibitors.

Structure-Based Optimization of the Piperazino-Containing 1,3-Disubstituted Ureas Affording Sub-Nanomolar Inhibitors of Soluble Epoxide Hydrolase

Discovery and optimization of piperazine urea derivatives as soluble epoxide hydrolase (sEH) inhibitors

Design, Synthesis, and In‐Vitro Evaluation of Novel Butanoic Acid Derivatives as Potential Soluble Epoxide Hydrolase Inhibitors

Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain

Discovery of glycosidated glycyrrhetinic acid derivatives: Natural product-based soluble epoxide hydrolase inhibitors

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Evaluation of the Therapeutic Potential of Sulfonyl Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors

Discovery of Novel Soluble Epoxide Hydrolase Inhibitors as Potent Vasodilators

Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis

Synthesis, In Vitro Enzymatic Inhibition, and Molecular Modeling of Novel Piperazine‐Based Bis‐Schiff Base Derivatives as Promising Anti‐urease Agents

Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors

Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products

Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors.

Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors

Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

Discovery and Optimization of Thienopyridine Derivatives As Novel Urea Transporter Inhibitors.

A Comprehensive Review of Soluble Epoxide Hyådrolase Inhibitors Evaluating their Structure-Activity Relationship

Probing Ligand-Binding Modes and Binding Mechanisms of Benzoxazole-Based Amide Inhibitors with Soluble Epoxide Hydrolase by Molecular Docking and Molecular Dynamics Simulation.

Structural insight into the lead identification of a dual inhibitor of PDE1B and PDE10A: Integrating pharmacophore-based virtual screening, molecular docking, and structure-activity-relationship approaches

Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors